Search Videos and More
News
Fox Chase Researcher Parth Desai Receives Prestigious ASCO Career Development Award
A Fox Chase Cancer Center researcher has received a prestigious national award to advance a novel immunotherapy strategy aimed at one of oncology's most persistent challenges: tumors that resist immune-based treatments.
News
New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer
A new study from researchers at Fox Chase Cancer Center and collaborators across multiple institutions has identified a hidden subset of lung cancers that behave more like aggressive neuroendocrine tumors than traditional non-small cell lung cancer (NSCLC).
News
First-in-Human Study Tests Gamitrinib Designed to Disrupt Cancer Cells’ Energy Systems
Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell’s “powerhouse.” Unlike healthy cells, cancer cells rely heavily on specialized helper proteins to keep mitochondria functioning under the high stress of rapid growth.
News
Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.
News
Fox Chase – Temple Urologic Institute at AUA 2026
Visit the Fox Chase-Temple Urologic Institute Booth #2464 in the Science & Technology Hall.
Symposium
24th Annual Highlights of the 2025 San Antonio Breast Cancer Symposium
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this education program is designed to help medical, radiation, and surgical oncologists, gynecologists, and radiologists translate the data from key presentations of the 2025 San Antonio Breast Cancer Symposium into practice. New options for the prevention, diagnosis, and treatment of breast cancer and premalignant breast disease will be discussed. In addition, we will address new strategies for optimizing existing treatments.
News
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).
News
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
News
New Program Will Improve Patient Access to Clinical Trials
A multidisciplinary team at Fox Chase Cancer Center has developed and tested a patient-centered education program designed to reduce barriers to clinical trial participation among kidney cancer patients.
News
Combined Tests Could Reduce Unnecessary Bladder Removal
Combining a visual inspection of the bladder with a blood test to check for the presence of circulating tumor DNA can accurately predict which bladder cancer patients still have cancer in their bladder after treatment — and which do not. The findings presented today by Fox Chase Cancer Center researchers could someday help urologists identify which bladder cancer patients can safely avoid undergoing bladder removal, a risky and life-altering surgery.
News
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.
News
Dose-Attenuated Chemotherapy in Patients with Lung Cancer and Age >/= 70 and/or Comorbidities
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.